Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.
AURA
12.1 as of 6/2/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 3/22/2021 | Series E | $80.48MM raised | $XXX.XX | $XXX.XX |
| 7/9/2020 | Series D-2 | $17MM raised | $XXX.XX | $XXX.XX |
| 4/2/2019 | Series D-1 | $40MM raised | $XXX.XX | $XXX.XX |
| 12/21/2017 | Series C-1 and C-2 | $42.41MM raised | $XXX.XX | $XXX.XX |
| 3/5/2015 | Series B | $28.21MM raised | $XXX.XX | $XXX.XX |
| 8/17/2014 | Series A-2 | $5.37MM raised | $XXX.XX | $XXX.XX |
| 7/4/2013 | Series A-1 | $8.2MM raised | $XXX.XX | $XXX.XX |
| 8/26/2011 | Series A | $3.4MM raised | $XXX.XX | $XXX.XX |
